New European rollout, Winlevi from Glenmark targets prescription acne segment

Glenmark’s specialty arm is rolling out Winlevi (clascoterone 10 mg/g cream) across key European markets, positioning the prescription acne therapy as a differentiated topical option after EU approval in 2025.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/16/2026 at 5:41 AM ET. Details in the imprint.

Glenmark Pharmaceuticals is pushing deeper into the European dermatology market with the rollout of Winlevi, a clascoterone 10 mg/g cream for acne that its Swiss-based subsidiary Glenmark Specialty S.A. is now launching in several key EU countries after centralized approval in 2025. The prescription-only topical, positioned for patients with acne vulgaris, aims to give dermatologists a new androgen-receptor-targeting option in a segment still dominated by retinoids and antibiotics.

What Glenmark’s Winlevi brings to Europe’s acne market

Winlevi (clascoterone 10 mg/g cream) is an anti-androgen topical indicated for the treatment of acne vulgaris in patients 12 years of age and older, and the product received European Commission marketing authorization in October 2025 following a positive opinion from the EMA. Cosmo’s statement on EU approval and recent launches highlights that it is described as the first acne cream in Europe to act as a topical androgen receptor inhibitor, differentiating it from standard benzoyl peroxide or topical retinoid therapies. Clinically, clascoterone works by blocking androgen receptors in the skin, reducing sebum production and inflammation at the follicular level, which are key drivers of acne lesions.

The launch across Austria, Germany and other European markets is part of a broader commercial agreement under which Glenmark is responsible for marketing Winlevi in Europe, excluding certain territories retained by originator Cosmo Pharmaceuticals. Cosmo, which developed clascoterone and previously licensed US rights to another partner, has framed the European rollout with Glenmark as a way to tap what it calls a large underpenetrated market for prescription acne therapies in adults as well as adolescents. For Glenmark, the product fits its strategy of building a specialty and branded generics portfolio in dermatology and respiratory therapy, areas it already flags as core verticals in its investor communications.

From a positioning perspective, Winlevi competes not only against older topical agents but also against systemic hormonal options such as oral anti-androgens and combination therapies, while offering a localized mechanism of action that may appeal to prescribers seeking to avoid systemic side effects. The cream is intended to be applied twice daily to affected areas, with phase 3 data cited by Cosmo showing reductions in inflammatory and non-inflammatory lesion counts over a 12-week treatment period in both male and female patients with moderate to severe acne. Safety data have so far emphasized that systemic exposure to clascoterone remains low with topical use, though standard monitoring for local irritation, erythema or dryness remains part of routine dermatology practice.

Commercial details such as list prices are being set at the national level in Europe, with reimbursement discussions proceeding market by market, meaning that out-of-pocket costs for patients will vary significantly between, for example, Germany’s statutory insurance system and private-pay segments in smaller countries. Dermatologists familiar with the product from scientific conferences expect initial uptake to concentrate in specialist practices before potentially broadening as guidelines incorporate topical androgen-receptor blockers, a process that typically lags formal approval by several years. For Glenmark, building medical-education campaigns and real-world evidence around Winlevi’s performance in European patient populations will be central to gaining share in a mature but still growing acne-treatment market.

Strategically, the Winlevi rollout underscores Glenmark’s emphasis on specialty brands to complement its established generics base, a shift the company has highlighted repeatedly to diversify margins beyond pure price-competitive products. According to recent Indian market commentary, the company has been introducing a series of new branded formulations annually, including dermatology products, while highlighting respiratory, dermatology and oncology as key segments for future growth. Recent coverage of Glenmark’s product introductions and performance notes multiple new launches in its home market and a broader tilt toward complex molecules and differentiated therapies, which provides context for the decision to partner on a first-in-class topical acne agent for Europe.

Within Glenmark’s portfolio, Winlevi sits under its specialty and out-licensing business alongside other dermatology assets, complementing its generics operations in Europe that include a broad range of oral and topical medicines supplied to pharmacies and hospitals. The company’s own materials stress its focus on regulated markets such as the EU and the US for specialty products, while continuing to tap emerging markets for volume-led generics growth. Glenmark’s investor presentation outlines dermatology as one of its core therapy areas and points to in-licensed or partnered products as a route to accelerate innovation without bearing full development risk. Shares of Glenmark Pharmaceuticals Limited (ISIN INE935A01035) most recently traded on the NSE in Mumbai in Indian rupees, reflecting investor attention on how specialty launches like Winlevi can contribute to its longer-term earnings mix.

Winlevi in brief: the key data

• Product: Winlevi (clascoterone 10 mg/g cream)
• Manufacturer: Glenmark Pharmaceuticals Ltd.
• Category: New Release/Launch - prescription dermatology
• Launch date: European Commission approval in October 2025; launches in select EU markets in 2026
• MSRP / Price: Country-specific pricing in European markets; reimbursed levels vary by national health system
• Availability: Prescription-only in selected European countries such as Germany and Austria via pharmacies
• Target audience: Patients 12 years and older with acne vulgaris under dermatological care
• Key differentiator / USP: First topical acne therapy in Europe acting as a local androgen receptor inhibitor

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.